ERAS - Erasca, Inc.
IEX Last Trade
2.6
-0.020 -0.769%
Share volume: 24,674
Last Updated: Thu 26 Dec 2024 08:30:27 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.62
-0.02
-0.76%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.63%
1 Month
-7.55%
3 Months
-5.17%
6 Months
16.82%
1 Year
18.43%
2 Year
-37.32%
Key data
Stock price
$2.60
DAY RANGE
$2.52 - $2.62
52 WEEK RANGE
$1.72 - $3.45
52 WEEK CHANGE
$16.82
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Jonathan E. Lim
Region: US
Website: erasca.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: erasca.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia.
Recent news